June 5, 2023 MedinCell will publish its annual results (April 2022-March 2023) on June 26, 2023 Read press release
May 22, 2023 Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile Read press release
May 12, 2023 MedinCell announces the successful pricing of its Global Offering and raises €25 million Read press release
May 11, 2023 MedinCell launches a Global Offering for approximately 25 million euros Read press release
May 4, 2023 mdc-TJK’s (Teva’s codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada) Read press release